Previous 10 | Next 10 |
Predictive Oncology (NASDAQ: POAI) , a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, is partnering with FluGen to bring a first-of-its-kind intranasal flu vaccine to market. According to the announcement, the partnership is part of a $6.2 million phas...
2024-04-30 16:45:52 ET More on Predictive Oncology Predictive Oncology Inc. (POAI) Q4 2023 Earnings Call Transcript Financial information for Predictive Oncology Read the full article on Seeking Alpha For further details see: Predictive Oncology stock ral...
PITTSBURGH, April 30, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, announces a collaboration with FluGen to bring a first-of-its-kind intranasal flu vaccine to market, as part of a $6.2 million Phase 2B grant awarded by...
2024-04-25 13:06:40 ET Gainers: Loar Holdings ( LOAR ) +63% . Safe & Green Holdings Corp ( SGBX ) +61% . YY Group Holding Limited Class A Ordinary Shares ( YYGH ) +50% . Barfresh Food Group ( BRFH ) +40% . Processa Pharmaceuticals ( ...
2024-04-25 10:00:28 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance BofA watched clients retract $2B last week as the S&P dropped ...
PITTSBURGH, April 24, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, which is be...
2024-04-19 10:00:25 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Short interest in S&P 500 health stocks rises, Moderna among m...
2024-04-01 10:25:24 ET Predictive Oncology Inc. (POAI) Q4 2023 Earnings Conference Call April 01, 2024 08:30 A.M. ET Company Participants Glenn Garmont - IR Raymond F. Vennare - CEO and Chairman Josh Blacher - Interim CFO Conference Call Participants ...
2024-03-29 01:12:42 ET More on Predictive Oncology Financial information for Predictive Oncology Read the full article on Seeking Alpha For further details see: Predictive Oncology GAAP EPS of -$3.48, revenue of $1.78M
PITTSBURGH, March 28, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology (Nasdaq: POAI) , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLIA laboratory and GMP facility, to accelerate onc...
News, Short Squeeze, Breakout and More Instantly...
Predictive Oncology Inc. Company Name:
POAI Stock Symbol:
NASDAQ Market:
Predictive Oncology Inc. Website:
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the introduction of a new technology designed to express functional and stable G-Protein Coupled Receptors (“GPCRs”). GPCRs are cell surface membrane receptors believed to play a...
Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development External sources value annual US GPCR market at nearly $3.5 billion in 2022, growing more than 5% annu...
Predictive Oncology (NASDAQ: POAI) , a leader in AI-driven drug discovery and biologics, today announced the availability of its unique 3D cell culture model to advance cancer drug discovery and enable future drug development. More closely mimicking human tissue architecture than traditional 2D a...